



Addition of an Addendum to the 2023 Immunization Schedules for Children/Adolescents and Adults

Sarah Schillie, MD, MPH, MBA
CAPT, US Public Health Service

Team Lead, Professional Education and Training, Immunization Services Division
Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices

September 22, 2023

Atlanta, GA

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

Immunization Schedules: Overview

- Two separate schedules
 - Child and adolescent schedule (age birth through 18 years)
 - Adult schedule (age 19 years or older)
- Multiple sections that summarize and aid in implementation of approved ACIP policy
 - Cover Page
 - Tables
 - Notes
 - Appendix

COVID-19 vaccination recommendations have changed. Find the latest recommendations at www.cdc.gov/covidschedule

Recommended Adult Immunization Schedule

for ages 19 years or older

UNITED STATES
2023

COVID-19 vaccination recommendations have changed. Find the latest recommendations at www.cdc.gov/covidschedule

Recommended Child and Adolescent Immunization Schedule

for ages 18 years or younger

UNITED STATES
2023

Vaccines in the Child and Adolescent Immunization Schedule*

Vaccine	Abbreviation(s)	Trade name(s)
COVID-19	1vCOV-mRNA	Comirnaty®/Pfizer-BioNTech COVID-19 Vaccine Spikevax®/Moderna COVID-19 Vaccine
	2vCOV-mRNA	Pfizer-BioNTech COVID-19 Vaccine, Bivalent Moderna COVID-19 Vaccine, Bivalent
	1vCOV-aPS	Novavax COVID-19 Vaccine
Dengue vaccine	DEMCYD	Dengvaxia®
Diphtheria, tetanus, and acellular pertussis vaccine	DTaP	Daptacel® Infanrix®
Diphtheria, tetanus vaccine	DT	No trade name
Haemophilus influenzae type b vaccine	Hib (PRP-T)	ActHib®
	Hib (PRP-OMP)	Hibent® PedvaxHib®
Hepatitis A vaccine	HepA	Harvix® Vaxneq®
Hepatitis B vaccine	HepB	Engerix-B® Recombivax HB®
Human papillomavirus vaccine	HPV	Gardasil 9®
Influenza vaccine (inactivated)	IV4	Multiple
Influenza vaccine (live, attenuated)	LAIV4	FluMist® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II® Priorix®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D	Menactra®
	MenACWY-CRM	Menveo®
	MenACWY-FTT	MenQuadfi®
Meningococcal serogroup B vaccine	MenB-4C	Bexsero®
	MenB-FHbp	Trumenba®
Pneumococcal conjugate vaccine	PCV13	Prevnar 13®
	PCV15	Vaxneuvac™
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23®
Poliovirus vaccine (inactivated)	IPV	IPOL®
Rotavirus vaccine	RV1	Rotarix®
	RV2	Rotitec®
Tetanus, diphtheria, and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Tetanus and diphtheria vaccine	Td	Teniva® Tdvax™
Varicella vaccine	VAR	Varivax®
COMBINATION VACCINES (not combination vaccines in the covered Appendix)		
DTaP, hepatitis B, and inactivated poliovirus vaccine	DTaP-HepB-IPV	Pentacel®
DTaP, inactivated poliovirus, and Haemophilus influenzae type b vaccine	DTaP-IPV/Hib	Pentacel®
DTaP and inactivated poliovirus vaccine	DTaP-IPV	Kinrix® Quadacel®
DTaP, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B vaccine	DTaP-IPV/Hib-HepB	Vaxelis®
Measles, mumps, rubella, and varicella vaccine	MMRV	ProQuad®

*Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

How to use the child and adolescent immunization schedule

- 1 Determine recommended vaccine by age (Table 1)
- 2 Determine recommended interval for catch-up vaccination (Table 2)
- 3 Assess need for additional recommended vaccines by medical condition or other indication (Table 3)
- 4 Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
- 5 Review contraindications and precautions for vaccine types (Appendix)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American Academy of Pediatrics (www.aap.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Assistants (www.aapa.org), and National Association of Pediatric Nurse Practitioners (www.napn.org).

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or 800-822-7967

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 9 a.m.–8 p.m. ET, Monday through Friday, excluding holidays

Helpful Information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- General Best Practice Guidelines for Immunization (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification, and outbreak response): www.cdc.gov/vaccines/pubs/surv-manual
- ACIP Shared Clinical Decision-Making Recommendations www.cdc.gov/vaccines/acip/acip-scdm-faqs.html

Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html

Scan QR code for access to online schedule

U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

Immunization Schedules: Overview, cont.

- **Published in 3 formats:**
 - PDF, webpage, app
- **Multiple professional organizations partner with CDC to approve schedules**
 - American College of Physicians (www.acponline.org)
 - American Academy of Family Physicians (www.aafp.org)
 - American College of Obstetricians and Gynecologists (www.acog.org)
 - American College of Nurse-Midwives (www.midwife.org)
 - American Academy of Physician Associates (www.aapa.org)
 - American Pharmacists Association (www.pharmacist.com)
 - Society for Healthcare Epidemiology of America (www.shea-online.org)
 - American Academy of Pediatrics (www.aap.org)
 - National Association of Pediatric Nurse Practitioners (www.napnap.org)
- **Some professional organizations publish the schedules**

Recommended Adult Immunization Schedule

for ages 19 years or older

2023

How to use the adult immunization schedule

- 1** Determine recommended vaccinations by age (**Table 1**)
- 2** Assess need for additional recommended vaccinations by medical condition or other indication (**Table 2**)
- 3** Review vaccine types, dosing frequencies and intervals, and considerations for special situations (**Notes**)
- 4** Review contraindications and precautions for vaccine types (**Appendix**)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American College of Physicians (www.acponline.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Associates (www.aapa.org), American Pharmacists Association (www.pharmacist.com), and Society for Healthcare Epidemiology of America (www.shea-online.org).

Vaccines in the Adult Immunization Schedule*

Vaccine	Abbreviation(s)	Trade name(s)
COVID-19 vaccine	1vCOV-mRNA	Comirnaty®/Pfizer-BioNTech COVID-19 Vaccine Spikevax®/Moderna COVID-19 Vaccine
	2vCOV-mRNA	Pfizer-BioNTech COVID-19 Vaccine, Bivalent Moderna COVID-19 Vaccine, Bivalent
	1vCOV-aPS	Novavax COVID-19 Vaccine
<i>Haemophilus influenzae</i> type b vaccine	Hib	ActHIB® Hiberix® PedvaxHIB®
Hepatitis A vaccine	HepA	Havrix® Vaqta®
Hepatitis A and hepatitis B vaccine	HepA-HepB	Twinrix®
Hepatitis B vaccine	HepB	Engerix-B® Hepisav-B® PreHevbrio® Recombivax HB®
Human papillomavirus vaccine	HPV	Gardasil 9®
Influenza vaccine (inactivated)	IIV4	Many brands
Influenza vaccine (live, attenuated)	LAIV4	FluMist® Quadrivalent
Influenza vaccine (recombinant)	RIV4	Flublok® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II® Priorix®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D	Menactra®
	MenACWY-CRM	Menveo®
	MenACWY-TT	MenQuadfi®
	MenB-4C	Bexsero®
Meningococcal serogroup B vaccine	MenB-FHbp	Trumenba®
	MenB-4D	Trumenba®
Pneumococcal conjugate vaccine	PCV15	Vaxneuvance™
	PCV20	Prenar 20™
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23®
Poliovirus vaccine	IPV	IPOL®
Tetanus and diphtheria toxoids	Td	Tenivac® Tdvax™
Tetanus and diphtheria toxoids and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Varicella vaccine	VAR	Varivax®
Zoster vaccine, recombinant	RZV	Shingrix

*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department
- Clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System at www.vaers.hhs.gov or 800-822-7967

Injury claims

All vaccines included in the adult immunization schedule except PPSV23, RZV, and COVID-19 vaccines are covered by the National Vaccine Injury Compensation Program (VICP). COVID-19 vaccines that are authorized or approved by the FDA are covered by the Countermeasures Injury Compensation Program (CICP). For more information, see www.hrsa.gov/vaccinecompensation or www.hrsa.gov/cicp.

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.



Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html.

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- General Best Practice Guidelines for Immunization (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/vaccines/pubs/surv-manual
- Travel vaccine recommendations: www.cdc.gov/travel
- Recommended Child and Adolescent Immunization Schedule, United States, 2023: www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html
- ACIP Shared Clinical Decision-Making Recommendations: www.cdc.gov/vaccines/acip/acip-scdm-faqs.html

Scan QR code for access to online schedule



CS310021-C



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

Table 1

COVID-19 vaccination recommendations have changed. Find the latest recommendations at www.cdc.gov/covidschedule
 Recommended Adult Immunization Schedule for ages 19 years or older, United States, 2023

Vaccine	19–26 years	27–49 years	50–64 years	≥65 years
COVID-19	2- or 3- dose primary series and booster (See Notes)			
Influenza inactivated (IIV4) or Influenza recombinant (RIV4)	1 dose annually			
Influenza live, attenuated (LAIV4)	1 dose annually			
Tetanus, diphtheria, pertussis (Tdap or Td)	1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (see notes)			
	1 dose Tdap, then Td or Tdap booster every 10 years			
Measles, mumps, rubella (MMR)	1 or 2 doses depending on indication (if born in 1957 or later)			For healthcare personnel, see notes
Varicella (VAR)	2 doses (if born in 1980 or later)		2 doses	
Zoster recombinant (RZV)	2 doses for immunocompromising conditions (see notes)		2 doses	
Human papillomavirus (HPV)	2 or 3 doses depending on age at initial vaccination or condition	27 through 45 years		
Pneumococcal (PCV15, PCV20, PPSV23)	1 dose PCV15 followed by PPSV23 OR 1 dose PCV20 (see notes)			See Notes
Hepatitis A (HepA)	2, 3, or 4 doses depending on vaccine			
Hepatitis B (HepB)	2, 3, or 4 doses depending on vaccine or condition			
Meningococcal A, C, W, Y (MenACWY)	1 or 2 doses depending on indication, see notes for booster recommendations			
Meningococcal B (MenB)	2 or 3 doses depending on vaccine and indication, see notes for booster recommendations			
	19 through 23 years			
Haemophilus influenzae type b (Hib)	1 or 3 doses depending on indication			

 Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection
 Recommended vaccination for adults with an additional risk factor or another indication
 Recommended vaccination based on shared clinical decision-making
 No recommendation/ Not applicable

Notes

COVID-19 vaccination recommendations have changed. Find the latest recommendations at www.cdc.gov/covidschedule
Recommended Adult Immunization Schedule for ages 19 years or older, United States, 2023

For vaccine recommendations for persons 18 years of age or younger, see the Recommended Child and Adolescent Immunization Schedule.

COVID-19 vaccination

Routine vaccination

- **Primary series:** 2-dose series at 0, 4-8 weeks (Moderna) or 2-dose series at 0, 3-8 weeks (Novavax, Pfizer-BioNTech)
- **Booster dose:** see www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html

Special situations

Persons who are moderately or severely immunocompromised

- **Primary series**
 - 3-dose series at 0, 4, 8 weeks (Moderna) or 3-dose series at 0, 3, 7 weeks (Pfizer-BioNTech)
 - 2-dose series at 0, 3 weeks (Novavax)
- **Booster dose:** see www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html
- **Pre-exposure prophylaxis (e.g., monoclonal antibodies)** may be considered to complement COVID-19 vaccination. See www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#immunocompromised

For Janssen COVID-19 Vaccine recipients see COVID-19 schedule at www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.

Note: Current COVID-19 schedule available at www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf. For more information on Emergency Use Authorization (EUA) indications for COVID-19 vaccines, please visit www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines

Haemophilus influenzae type b vaccination

Special situations

- **Anatomical or functional asplenia (including sickle cell disease):** 1 dose if previously did not receive Hib; if elective splenectomy, 1 dose preferably at least 14 days before splenectomy
- **Hematopoietic stem cell transplant (HSCT):** 3-dose series 4 weeks apart starting 6–12 months after successful transplant, regardless of Hib vaccination history

Hepatitis A vaccination

Routine vaccination

- **Not at risk but want protection from hepatitis A** (identification of risk factor not required): 2-dose series HepA (Havrix 6–12 months apart or Vaqta 6–18 months apart [minimum interval: 6 months]) or 3-dose series HepA-HepB (Twinrix at 0, 1, 6 months [minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 5 months])

Special situations

- **At risk for hepatitis A virus infection:** 2-dose series HepA or 3-dose series HepA-HepB as above
 - **Chronic liver disease** (e.g., persons with hepatitis B, hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal)
 - **HIV infection**
 - **Men who have sex with men**
 - **Injection or noninjection drug use**
 - **Persons experiencing homelessness**
 - **Work with hepatitis A virus** in research laboratory or with nonhuman primates with hepatitis A virus infection

- **Travel in countries with high or intermediate endemic hepatitis A** (HepA-HepB [Twinrix] may be administered on an accelerated schedule of 3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months)

- **Close, personal contact with international adoptee** (e.g., household or regular babysitting) in first 60 days after arrival from country with high or intermediate endemic hepatitis A (administer dose 1 as soon as adoption is planned, at least 2 weeks before adoptee's arrival)

- **Pregnancy** if at risk for infection or severe outcome from infection during pregnancy

- **Settings for exposure**, including health care settings targeting services to injection or noninjection drug users or group homes and nonresidential day care facilities for developmentally disabled persons (individual risk factor screening not required)

Hepatitis B vaccination

Routine vaccination

- **Age 19 through 59 years: complete a 2- or 3- or 4-dose series**
 - 2-dose series only applies when 2 doses of Heplisav-B* are used at least 4 weeks apart
 - 3-dose series Engerix-B, PreHevbrio*, or Recombivax HB at 0, 1, 6 months [minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 8 weeks / dose 1 to dose 3: 16 weeks]
 - 3-dose series HepA-HepB (Twinrix at 0, 1, 6 months [minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 5 months])
 - 4-dose series HepA-HepB (Twinrix) accelerated schedule of 3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months

***Note:** Heplisav-B and PreHevbrio are not recommended in pregnancy due to lack of safety data in pregnant persons.

Appendix

Recommended Adult Immunization Schedule, United States, 2023

Guide to Contraindications and Precautions to Commonly Used Vaccines

Adapted from Table 4-1 in Advisory Committee on Immunization Practices (ACIP) General Best Practice Guidelines for Immunization: Contraindication and Precautions available at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html and ACIP's Recommendations for the Prevention and Control of 2022-23 Seasonal Influenza with Vaccines available at www.cdc.gov/mmwr/volumes/71/rr/rr7101a1.htm

For COVID-19 vaccine contraindications and precautions see

www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#contraindications


Vaccine	Contraindicated or Not Recommended ¹	Precautions ²
Influenza, egg-based, inactivated injectable (IIV4)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, cclIV, RIV, or LAIV of any valency) Severe allergic reaction (e.g., anaphylaxis) to any vaccine component³ (excluding egg) 	<ul style="list-style-type: none"> Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Moderate or severe acute illness with or without fever
Influenza, cell culture-based inactivated injectable [(cclIV4), Flucelvax [®] Quadrivalent]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) to any cclIV of any valency, or to any component³ of cclIV4 	<ul style="list-style-type: none"> Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, RIV, or LAIV of any valency. If using cclIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Moderate or severe acute illness with or without fever
Influenza, recombinant injectable [(RIV4), Flublok [®] Quadrivalent]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency, or to any component³ of RIV4 	<ul style="list-style-type: none"> Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, cclIV, or LAIV of any valency. If using RIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Moderate or severe acute illness with or without fever
Influenza, live attenuated [LAIV4, Flumist [®] Quadrivalent]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, cclIV, RIV, or LAIV of any valency) Severe allergic reaction (e.g., anaphylaxis) to any vaccine component³ (excluding egg) Anatomic or functional asplenia Immunocompromised due to any cause including, but not limited to, medications and HIV infection Close contacts or caregivers of severely immunosuppressed persons who require a protected environment Pregnancy Cochlear implant Active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, ear, or any other cranial CSF leak Received influenza antiviral medications oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir within the previous 17 days. 	<ul style="list-style-type: none"> Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Asthma in persons aged 5 years old or older Persons with underlying medical conditions (other than those listed under contraindications) that might predispose to complications after wild-type influenza virus infection [e.g., chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)] Moderate or severe acute illness with or without fever

1. When a contraindication is present, a vaccine should NOT be administered. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html

2. When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html

3. Vaccination providers should check FDA-approved prescribing information for the most complete and updated information, including contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states.

Traditional Publication Timeline



Impacts of Timeliness of Schedule Publication

- Insurance reimbursement
- The ability of certain health care providers to administer immunizations
 - Some states link pharmacists' immunization authority to the schedule
- Health care provider knowledge and practices related to immunization recommendations

Affordable Care Act: Immunization Coverage

- **Must provide coverage for and must not impose any cost-sharing requirements (such as a copayment, coinsurance, or a deductible) for—**

*“Immunizations for routine use in children, adolescents, and adults that have in effect a recommendation from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention...” “...considered in effect after it has been adopted by the Director of the Centers for Disease Control and Prevention, **and a recommendation is considered to be for routine use if it is listed on the Immunization Schedules of the Centers for Disease Control and Prevention)**”*

- **ACA does not specify what defines the Immunization Schedule**
 - Legally, CDC has discretion regarding what constitutes the immunization schedule

3-Pronged Approach to Address Schedule Timeliness, Maximize Utility

Immediate Strategy

Addition of Addenda will help bring the schedule up-to-date

Short-term Strategy

Publish entirety of schedule soon after October ACIP vote

Longer-term Strategy

Consider sustainable approach to ensure schedule remains dynamic/responsive and current (proposal in early in CY24)

Ensure partner engagement in planning process

Addition of Addenda to 2023 Immunization Schedules

- **Contain ACIP recommendations that occurred after the 2023 schedule was published**
- **Plan to release 2023 Immunization Schedules with Addenda next week**
- **With this addition, all ACIP recommendations will formally be part of the CDC Immunization Schedules**

Recommended Adult Immunization Schedule for ages 19 years or older

2023

How to use the adult immunization schedule

- 1** Determine recommended vaccinations by age (Table 1)
- 2** Assess need for additional recommended vaccinations by medical condition or other indication (Table 2)
- 3** Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- 4** Review contraindications and precautions for vaccine types (Appendix)
- 5** Review new or updated ACIP guidance (Addendum)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American College of Physicians (www.acponline.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Associates (www.aapa.org), American Pharmacists Association (www.pharmacist.com), and Society for Healthcare Epidemiology of America (www.shea-online.org).

Vaccines in the Adult Immunization Schedule*

Vaccine	Abbreviation(s)	Trade name(s)
COVID-19 vaccine [†]	1vCOV-mRNA	Comirnaty*/Pfizer-BioNTech COVID-19 Vaccine Spikevax*/Moderna COVID-19 Vaccine
	2vCOV-mRNA	Pfizer-BioNTech COVID-19 Vaccine, Bivalent Moderna COVID-19 Vaccine, Bivalent
	1vCOV-aPS	Novavax COVID-19 Vaccine
Haemophilus influenzae type b vaccine	Hib	ActHIB* Hiberix* PedvaxHIB*
Hepatitis A vaccine	HepA	Havrix* Vaqta*
Hepatitis A and hepatitis B vaccine	HepA-HepB	Twinrix*
Hepatitis B vaccine	HepB	Engerix-B* Hepilisav-B* PreHevbrio* Recombivax HB*
Human papillomavirus vaccine	HPV	Gardasil 9*
Influenza vaccine (inactivated) [†]	IIV4	Many brands
Influenza vaccine (live, attenuated) [†]	LAIV4	FluMist* Quadrivalent
Influenza vaccine (recombinant) [†]	RIV4	Flublok* Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II* Priorix*
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D	Menactra*
	MenACWY-CRM	Menveo*
	MenACWY-TT	MenQuadfi*
	MenB-4C MenB-FHbp	Bexsero* Trumenba*
Pneumococcal conjugate vaccine	PCV15	Vaxneuvance™
	PCV20	Prenar 20™
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23*
Poliovirus vaccine [†]	IPV	IPOL*
Tetanus and diphtheria toxoids	Td	Tenivac* Tdvax™
Tetanus and diphtheria toxoids and acellular pertussis vaccine	Tdap	Adacel* Boostrix*
Varicella vaccine	VAR	Varivax*
Zoster vaccine, recombinant	RZV	Shingrix
New Vaccines added to the Adult Immunization Schedule in 2023 (See Addendum)		
Respiratory Syncytial Virus vaccine	RSV	Arexvy* ABRYOVO™

*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

[†] COVID-19, Poliovirus, and Influenza vaccines have new or updated ACIP recommendations. Please see Addendum for more details.

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department
- Clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System at www.vaers.hhs.gov or 800-822-7967

Injury claims

All vaccines included in the adult immunization schedule except PPSV23, RZV, and COVID-19 vaccines are covered by the National Vaccine Injury Compensation Program (VICP). COVID-19 vaccines that are authorized or approved by the FDA are covered by the Countermeasures Injury Compensation Program (CICP). For more information, see www.hrsa.gov/vaccinecompensation or www.hrsa.gov/cicp.

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.



Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html.

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- *General Best Practice Guidelines for Immunization* (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/vaccines/pubs/surv-manual
- Travel vaccine recommendations: www.cdc.gov/travel
- Recommended Child and Adolescent Immunization Schedule, United States, 2023: www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html
- ACIP Shared Clinical Decision-Making Recommendations: www.cdc.gov/vaccines/acip/acip-scdm-faqs.html

Scan QR code for access to online schedule



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

See Addendum for new or updated ACIP vaccine recommendations

Recommended Adult Immunization Schedule for ages 19 years or older

2023

How to use the adult immunization schedule

- 1** Determine recommended vaccinations by age (Table 1)
- 2** Assess need for additional recommended vaccinations by medical condition or other indication (Table 2)
- 3** Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- 4** Review contraindications and precautions for vaccine types (Appendix)
- 5** Review new or updated ACIP guidance (Addendum)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American College of Physicians (www.acponline.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Associates (www.aapa.org), American Pharmacists Association (www.pharmacist.com), and Society for Healthcare Epidemiology of America (www.shea-online.org).

Vaccines in the Adult Immunization Schedule*

Vaccine	Abbreviation(s)	Trade name(s)
COVID-19 vaccine [†]	1vCOV-mRNA	Comirnaty*/Pfizer-BioNTech COVID-19 Vaccine Spikevax*/Moderna COVID-19 Vaccine
	2vCOV-mRNA	Pfizer-BioNTech COVID-19 Vaccine, Bivalent Moderna COVID-19 Vaccine, Bivalent
	1vCOV-aPS	Novavax COVID-19 Vaccine
Haemophilus influenzae type b vaccine	Hib	ActHIB* Hiberix* PedvaxHIB*
Hepatitis A vaccine	HepA	Havrix* Vaqta*
Hepatitis A and hepatitis B vaccine	HepA-HepB	Twinrix*
Hepatitis B vaccine	HepB	Engerix-B* Hepilisav-B* PreHevbrio* Recombivax HB*
Human papillomavirus vaccine	HPV	Gardasil 9*
Influenza vaccine (inactivated) [†]	IIV4	Many brands
Influenza vaccine (live, attenuated) [†]	LAIV4	FluMist* Quadrivalent
Influenza vaccine (recombinant) [†]	RIV4	Flublok* Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II* Priorix*
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D	Menactra*
	MenACWY-CRM	Menveo*
	MenACWY-TT	MenQuadfi*
	MenB-4C	Bexsero*
Meningococcal serogroup B vaccine	MenB-FHbp	Trumenba*
	PCV15	Vaxneuvance™
Pneumococcal conjugate vaccine	PCV20	Prenar 20™
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23*
Poliovirus vaccine [†]	IPV	IPOL*
Tetanus and diphtheria toxoids	Td	Tenivac* Tdvax™
	Tdap	Adacel* Boostrix* Varivax* Shingrix
Tetanus and diphtheria toxoids and acellular pertussis vaccine	VAR	Varivax*
Varicella vaccine	RZV	Shingrix
Zoster vaccine, recombinant		
New Vaccines added to the Adult Immunization Schedule in 2023 (See Addendum)		
Respiratory Syncytial Virus vaccine	RSV	Arexvy* ABRYVO™

*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

[†] COVID-19, Poliovirus, and Influenza vaccines have new or updated ACIP recommendations. Please see Addendum for more details.

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department
- Clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System at www.vaers.hhs.gov or 800-822-7967

Injury claims

All vaccines included in the adult immunization schedule except PPSV23, RZV, and COVID-19 vaccines are covered by the National Vaccine Injury Compensation Program (VICP). COVID-19 vaccines that are authorized or approved by the FDA are covered by the Countermeasures Injury Compensation Program (CICP). For more information, see www.hrsa.gov/vaccinecompensation or www.hrsa.gov/cicp.

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.



Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html.

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- *General Best Practice Guidelines for Immunization* (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/vaccines/pubs/surv-manual
- Travel vaccine recommendations: www.cdc.gov/travel
- Recommended Child and Adolescent Immunization Schedule, United States, 2023: www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html
- ACIP Shared Clinical Decision-Making Recommendations: www.cdc.gov/vaccines/acip/acip-scdm-faqs.html

Scan QR code for access to online schedule



U.S. Department of
Health and Human Services
Centers for Disease
Control and Prevention

See Addendum for new or updated ACIP vaccine recommendations

Recommended Adult Immunization Schedule for ages 19 years or older

2023

How to use the adult immunization schedule

- 1 Determine recommended vaccinations by age (Table 1)
- 2 Assess need for additional recommended vaccinations by medical condition or other indication (Table 2)
- 3 Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- 4 Review contraindications and precautions for vaccine types (Appendix)
- 5 Review new or updated ACIP guidance (Addendum)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American College of Physicians and Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Associates (www.aapa.org), American Pharmacists Association (www.pharmacist.com), and Society for Healthcare Epidemiology of America (www.shea-online.org).

Vaccines in the Adult Immunization Schedule*

Vaccine	Abbreviation(s)	Trade name(s)
COVID-19 vaccine†	1vCOV-mRNA	Comirnaty*/Pfizer-BioNTech COVID-19 Vaccine Spikevax*/Moderna COVID-19 Vaccine
	2vCOV-mRNA	Pfizer-BioNTech COVID-19 Vaccine, Bivalent Moderna COVID-19 Vaccine, Bivalent
Haemophilus influenzae type b vaccine	1vCOV-aPS	Novavax COVID-19 Vaccine
	Hib	ActHIB* Hiberix* PedvaxHIB*
Hepatitis A vaccine	HepA	Havrix* Vaqta*
Hepatitis A and hepatitis B vaccine	HepA-HepB	Twinrix*
Hepatitis B vaccine	HepB	Engerix-B* Heplisav-B* PreHevbrio* Recombivax HB*
Human papillomavirus vaccine	HPV	Gardasil 9*
Influenza vaccine (inactivated)†	IIV4	Many brands
Influenza vaccine (live, attenuated)†	LAIV4	FluMist* Quadrivalent
Influenza vaccine (recombinant)†	RIV4	Flublok* Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II* Priorix*
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D	Menactra*
	MenACWY-CRM	Menveo*
	MenACWY-TT	MenQuadfi*
Meningococcal serogroup B vaccine	MenB-4C	Bexsero*
	MenB-FHbp	Trumenba*
Pneumococcal conjugate vaccine	PCV15	Vaxneuvance™
	PCV20	Prenvax 20™
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23*
Poliovirus vaccine†	IPV	IPOL*
Tetanus and diphtheria toxoids	Td	Tenivac* Tdvax™
	Tdap	Adacel* Boostrix*
Tetanus and diphtheria toxoids and acellular pertussis vaccine	Tdap	Adacel* Boostrix*
Varicella vaccine	VAR	Varivax*
Zoster vaccine, recombinant	RZV	Shingrix
New Vaccines added to the Adult Immunization Schedule in 2023 (See Addendum)		
Respiratory Syncytial Virus vaccine	RSV	Arexvy* ABRYVO™

*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

† COVID-19, Poliovirus, and Influenza vaccines have new or updated ACIP recommendations. Please see Addendum for more details.

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department
- Clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System at www.vaers.hhs.gov or 800-822-7967

Injury claims

All vaccines included in the adult immunization schedule except PPSV23, RZV, and COVID-19 vaccines are covered by the National Vaccine Injury Compensation Program (VICP). COVID-19 vaccines that are authorized or approved by the FDA are covered by the Countermeasures Injury Compensation Program (CICP). For more information, see www.hrsa.gov/vaccinecompensation or www.hrsa.gov/cicp.

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.



Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html.

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- General Best Practice Guidelines for Immunization (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/vaccines/pubs/surv-manual
- Travel vaccine recommendations: www.cdc.gov/travel
- Recommended Child and Adolescent Immunization Schedule, United States, 2023: www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html
- ACIP Shared Clinical Decision-Making Recommendations: www.cdc.gov/vaccines/acip/acip-scdm-faqs.html

Scan QR code for access to online schedule



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

CS310021-C

See Addendum for new or updated ACIP vaccine recommendations

Recommended Adult Immunization Schedule for ages 19 years or older

2023

How to use the adult immunization schedule

- 1** Determine recommended vaccinations by age (Table 1)
- 2** Assess need for additional recommended vaccinations by medical condition or other indication (Table 2)
- 3** Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- 4** Review contraindications and precautions for vaccine types (Appendix)
- 5** Review new or updated ACIP guidance (Addendum)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American College of Physicians and Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Associates (www.aapa.org), American Pharmacists Association (www.pharmacist.com), and Society for Healthcare Epidemiology of America (www.shea-online.org).

Vaccines in the Adult Immunization Schedule*

Vaccine	Abbreviation(s)	Trade name(s)
COVID-19 vaccine†	1vCOV-mRNA	Comirnaty*/Pfizer-BioNTech COVID-19 Vaccine Spikevax*/Moderna COVID-19 Vaccine
	2vCOV-mRNA	Pfizer-BioNTech COVID-19 Vaccine, Bivalent Moderna COVID-19 Vaccine, Bivalent
Haemophilus influenzae type b vaccine	1vCOV-aPS	Novavax COVID-19 Vaccine
	Hib	ActHIB* Hiberix* PedvaxHIB*
Hepatitis A vaccine	HepA	Havrix* Vaqta*
Hepatitis A and hepatitis B vaccine	HepA-HepB	Twinrix*
Hepatitis B vaccine	HepB	Engerix-B* HepLisav-B* PreHevbrio* Recombivax HB*
Human papillomavirus vaccine	HPV	Gardasil 9*
Influenza vaccine (inactivated)‡	IIV4	Many brands
Influenza vaccine (live, attenuated)‡	LAIV4	FluMist* Quadrivalent
Influenza vaccine (recombinant)‡	RIV4	Flublok* Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II* Priorix*
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D	Menactra*
	MenACWY-CRM	Menveo*
	MenACWY-TT	MenQuadfi*
Meningococcal serogroup B vaccine	MenB-4C	Bexsero*
	MenB-FHbp	Trumenba*
Pneumococcal conjugate vaccine	PCV15	Vaxneuvance™
	PCV20	Prenar 20™
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23*
Poliovirus vaccine†	IPV	IPOL*
Tetanus and diphtheria toxoids	Td	Tenivac* Tdvax™
	Tdap	Adacel* Boostrix*
Tetanus and diphtheria toxoids and acellular pertussis vaccine	Tdap	Adacel* Boostrix*
Varicella vaccine	VAR	Varivax*
Zoster vaccine, recombinant	RZV	Shingrix
New Vaccines added to the Adult Immunization Schedule in 2023 (See Addendum)		
Respiratory Syncytial Virus vaccine	RSV	Arexvy* ABRYVO™

*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

† COVID-19, Poliovirus, and Influenza vaccines have new or updated ACIP recommendations. Please see Addendum for more details.

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department
- Clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System at www.vaers.hhs.gov or 800-822-7967

Injury claims

All vaccines included in the adult immunization schedule except PPSV23, RZV, and COVID-19 vaccines are covered by the National Vaccine Injury Compensation Program (VICP). COVID-19 vaccines that are authorized or approved by the FDA are covered by the Countermeasures Injury Compensation Program (CICP). For more information, see www.hrsa.gov/vaccinecompensation or www.hrsa.gov/cicp.

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.



Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html.

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- General Best Practice Guidelines for Immunization (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/vaccines/pubs/surv-manual
- Travel vaccine recommendations: www.cdc.gov/travel
- Recommended Child and Adolescent Immunization Schedule, United States, 2023: www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html
- ACIP Shared Clinical Decision-Making Recommendations: www.cdc.gov/vaccines/acip/acip-scdm-faqs.html

Scan QR code for access to online schedule



CS310021-C



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

Addendum

Recommended Adult Immunization Schedule, United States, 2023

In addition to the recommendations presented in the previous sections of this Immunization Schedule, ACIP has approved the following recommendations by majority vote since October 20, 2022. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in *Morbidity and Mortality Weekly Report (MMWR)*.

Vaccines	Recommendations	Effective Date of Recommendation*
COVID-19 (Moderna, Pfizer-BioNTech)	<ul style="list-style-type: none">All persons ≥ 6 months of age should receive 2023–2024 (monovalent, XBB containing) COVID-19 vaccines as authorized under EUA or approved by BLA.For detailed information, see: www.cdc.gov/covidschedule	September 12, 2023
Respiratory syncytial virus (RSV)	<ul style="list-style-type: none">Adults 60 years of age and older may receive a single dose of Respiratory Syncytial Virus (RSV) vaccine, using shared clinical decision-making.For detailed information, see: www.cdc.gov/mmwr/volumes/72/wr/mm7229a4.htm?s_cid=mm7229a4_w	June 27, 2023
Poliovirus (IPV)	<ul style="list-style-type: none">Adults who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary vaccination series with inactivated polio vaccine (IPV).Adults who have received a primary series of trivalent oral polio vaccine (tOPV) or IPV in any combination and who are at increased risk of poliovirus exposure may receive another dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose with IPV for adults.	June 27, 2023
Influenza (IIV4, cclV4, RIV4, LAIV4)	<ul style="list-style-type: none">All persons ages ≥ 6 months with egg allergy should receive influenza vaccine. Any influenza vaccine (egg based or non-egg based) that is otherwise appropriate for the recipient's age and health status can be used.Affirm the updated <i>MMWR</i> Recommendations and Reports, "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023-24 Influenza Season" www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm	June 27, 2023

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official

Addendum

Recommended Adult Immunization Schedule, United States, 2023

In addition to the recommendations presented in the previous sections of this Immunization Schedule, ACIP has approved the following recommendations by majority vote since October 20, 2022. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in *Morbidity and Mortality Weekly Report (MMWR)*.

Vaccines	Recommendations	Effective Date of Recommendation*
COVID-19 (Moderna, Pfizer-BioNTech)	<ul style="list-style-type: none">All persons ≥ 6 months of age should receive 2023–2024 (monovalent, XBB containing) COVID-19 vaccines as authorized under EUA or approved by BLA.For detailed information, see: www.cdc.gov/covidschedule	September 12, 2023
Respiratory syncytial virus (RSV)	<ul style="list-style-type: none">Adults 60 years of age and older may receive a single dose of Respiratory Syncytial Virus (RSV) vaccine, using shared clinical decision-making.For detailed information, see: www.cdc.gov/mmwr/volumes/72/wr/mm7229a4.htm?s_cid=mm7229a4_w	June 27, 2023
Poliovirus (IPV)	<ul style="list-style-type: none">Adults who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary vaccination series with inactivated polio vaccine (IPV).Adults who have received a primary series of trivalent oral polio vaccine (tOPV) or IPV in any combination and who are at increased risk of poliovirus exposure may receive another dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose with IPV for adults.	June 27, 2023
Influenza (IIV4, cclV4, RIV4, LAIV4)	<ul style="list-style-type: none">All persons ages ≥ 6 months with egg allergy should receive influenza vaccine. Any influenza vaccine (egg based or non-egg based) that is otherwise appropriate for the recipient's age and health status can be used.Affirm the updated <i>MMWR</i> Recommendations and Reports, "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023-24 Influenza Season" www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm	June 27, 2023

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official

Addendum

Recommended Adult Immunization Schedule, United States, 2023

In addition to the recommendations presented in the previous sections of this Immunization Schedule, ACIP has approved the following recommendations by majority vote since October 20, 2022. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in *Morbidity and Mortality Weekly Report (MMWR)*.

Vaccines	Recommendations	Effective Date of Recommendation*
COVID-19 (Moderna, Pfizer-BioNTech)	<ul style="list-style-type: none"> All persons ≥ 6 months of age should receive 2023–2024 (monovalent, XBB containing) COVID-19 vaccines as authorized under EUA or approved by BLA. For detailed information, see: www.cdc.gov/covidschedule 	September 12, 2023
Respiratory syncytial virus (RSV)	<ul style="list-style-type: none"> Adults 60 years of age and older may receive a single dose of Respiratory Syncytial Virus (RSV) vaccine, using shared clinical decision-making. For detailed information, see: www.cdc.gov/mmwr/volumes/72/wr/mm7229a4.htm?s_cid=mm7229a4_w 	June 27, 2023
Poliovirus (IPV)	<ul style="list-style-type: none"> Adults who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary vaccination series with inactivated polio vaccine (IPV). Adults who have received a primary series of trivalent oral polio vaccine (tOPV) or IPV in any combination and who are at increased risk of poliovirus exposure may receive another dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose with IPV for adults. 	June 27, 2023
Influenza (IIV4, cclV4, RIV4, LAIV4)	<ul style="list-style-type: none"> All persons ages ≥ 6 months with egg allergy should receive influenza vaccine. Any influenza vaccine (egg based or non-egg based) that is otherwise appropriate for the recipient's age and health status can be used. Affirm the updated <i>MMWR</i> Recommendations and Reports, "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023-24 Influenza Season" www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm 	June 27, 2023

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official

Addendum

Recommended Adult Immunization Schedule, United States, 2023

In addition to the recommendations presented in the previous sections of this Immunization Schedule, ACIP has approved the following recommendations by majority vote since October 20, 2022. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in *Morbidity and Mortality Weekly Report (MMWR)*.

Vaccines	Recommendations	Effective Date of Recommendation*
COVID-19 (Moderna, Pfizer-BioNTech)	<ul style="list-style-type: none">All persons ≥ 6 months of age should receive 2023–2024 (monovalent, XBB containing) COVID-19 vaccines as authorized under EUA or approved by BLA.For detailed information, see: www.cdc.gov/covidschedule	September 12, 2023
Respiratory syncytial virus (RSV)	<ul style="list-style-type: none">Adults 60 years of age and older may receive a single dose of Respiratory Syncytial Virus (RSV) vaccine, using shared clinical decision-making.For detailed information, see: www.cdc.gov/mmwr/volumes/72/wr/mm7229a4.htm?s_cid=mm7229a4_w	June 27, 2023
Poliovirus (IPV)	<ul style="list-style-type: none">Adults who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary vaccination series with inactivated polio vaccine (IPV).Adults who have received a primary series of trivalent oral polio vaccine (tOPV) or IPV in any combination and who are at increased risk of poliovirus exposure may receive another dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose with IPV for adults.	June 27, 2023
Influenza (IIV4, cclV4, RIV4, LAIV4)	<ul style="list-style-type: none">All persons ages ≥ 6 months with egg allergy should receive influenza vaccine. Any influenza vaccine (egg based or non-egg based) that is otherwise appropriate for the recipient's age and health status can be used.Affirm the updated <i>MMWR</i> Recommendations and Reports, "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023-24 Influenza Season" www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm	June 27, 2023

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official

Addendum

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2023

In addition to the recommendations presented in the previous sections of this Immunization Schedule, ACIP has approved the following recommendations by majority vote since October 20, 2022. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in *Morbidity and Mortality Weekly Report (MMWR)*.

Vaccines and Other Immunizing Agents	Recommendation	Effective Date of Recommendation*
COVID-19 (Moderna, Pfizer-BioNTech)	<ul style="list-style-type: none"> All persons ≥ 6 months of age should receive 2023–2024 (monovalent, XBB containing) COVID-19 vaccines as authorized under EUA or approved by BLA. For detailed information, see: www.cdc.gov/covidschedule 	September 12, 2023
Respiratory syncytial virus [RSV-mAb (Nirsevimab)]	<ul style="list-style-type: none"> All infants younger than 8 months and born shortly before or during the RSV season should receive 1 dose of nirsevimab within 1 week of birth either in hospital or outpatient setting Infants younger than age 8 months not born during RSV season and now entering their first RSV season should receive 1 dose of nirsevimab shortly before the start of RSV season Infants aged 8–19 months with chronic lung disease of prematurity requiring medical support (e.g., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before start of the second RSV season; severe immunocompromise; cystic fibrosis with weight for length <10th percentile; or with manifestation of severe lung disease (e.g., previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable) should receive 1 dose of nirsevimab shortly before start of second RSV season Infants 8–19 months who are American Indian or Alaska Native should receive 1 dose of nirsevimab before start of second RSV season Infants who are age-eligible and undergoing cardiac surgery with cardiopulmonary bypass should receive 1 additional dose of nirsevimab after surgery For detailed information, see: www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm?s_cid=mm7234a4_w 	August 3, 2023
Poliovirus (IPV)	<ul style="list-style-type: none"> Adolescents age 18 years who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary vaccination series with inactivated polio vaccine (IPV). Adolescents age 18 years who have received a primary series of trivalent oral polio vaccine (tOPV) or IPV in any combination and who are at increased risk of poliovirus exposure may receive another dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose with IPV for adults. 	June 27, 2023
Influenza (IIV4, cdlV4, RIV4, LAIV4)	<ul style="list-style-type: none"> All persons ages ≥ 6 months with egg allergy should receive influenza vaccine. Any influenza vaccine (egg based or non-egg based) that is otherwise appropriate for the recipient's age and health status can be used. Affirm the updated <i>MMWR</i> Recommendations and Reports, "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 Influenza Season" www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm 	June 27, 2023
Pneumococcal (PCV15, PCV20)	<ul style="list-style-type: none"> Use of either pneumococcal conjugate vaccines (PCV) PCV15 or PCV20 is recommended for all children aged 2–23 months according to currently recommended PCV dosing and schedules. For children with an incomplete PCV vaccination status, use of either PCV15 or PCV20 according to currently recommended PCV dosing and schedules is recommended for: <ul style="list-style-type: none"> Healthy children aged 24–59 months Children with specified health conditions(2) aged 24 through 71 months For children aged 2–18 years with any risk condition who have received all recommended doses of PCV before age 6 years <ul style="list-style-type: none"> Using ≥ 1 dose(s) of PCV20: No additional doses of any pneumococcal vaccine are indicated. This recommendation may be updated as additional data become available. Using PCV13 or PCV15 (no PCV20): A dose of PCV20 or PPSV23 using previously recommended dosing and schedules is recommended. For children aged 6–18 years with any risk condition who have not received any dose of PCV13, PCV15, or PCV20, a single dose of PCV15 or PCV20 is recommended. When PCV15 is used, it should be followed by a dose of PPSV23 at least 8 weeks later if not previously given. 	June 27, 2023

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official

Summary

- **Anticipate release of 2023 Immunization Schedules with Addenda next week**
 - Formally incorporate all ACIP recommendations into 2023 CDC Immunization Schedule

- **Plan for short- and long-term sustainable strategies to address schedule timeliness**
 - Ensure partner engagement

Acknowledgements

**Immunization Services Division and
Health Education and Communication Branch staff, especially:**

- Neil Murthy
- Patricia Wodi
- Rosa Herrera
- Richard Quartarone
- Akiko Wilson

Questions?

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



Additional Slides

CDC Resources based off the Immunization Schedules

- Adult Vaccine Assessment Tool
- Child and Adolescent Vaccine Assessment Tool
- Parent Friendly



2023 Recommended Immunizations for Children from Birth Through 6 Years Old

VACCINE	Birth	1 MONTH	2 MONTHS	4 MONTHS	6 MONTHS	12 MONTHS	15 MONTHS	18 MONTHS	19-23 MONTHS	2-3 YEARS	4-6 YEARS
HepB Hepatitis B	HepB	HepB			HepB						
RV* Rotavirus			RV	RV	RV*						
DTaP Diphtheria, Pertussis, & Tetanus			DTaP	DTaP	DTaP		DTaP				DTaP
Hib* Haemophilus influenzae type b			Hib	Hib	Hib*	Hib					
PCV13, PCV15 Pneumococcal disease			PCV	PCV	PCV	PCV					
IPV Polio			IPV	IPV	IPV						IPV
COVID-19** Coronavirus disease 2019					COVID-19**						
Flu† Influenza					Flu (One or Two Doses Yearly)†						
MMR Measles, Mumps, & Rubella						MMR					MMR
Varicella Chickenpox						Varicella					Varicella
HepA* Hepatitis A						HepA*		HepA*			

FOOTNOTES

RV* **Hib***
Administering a third dose at age 6 months depends on the brand of Hib or rotavirus vaccine used for previous dose.

COVID-19** Number of doses recommended depends on your child's age and type of COVID-19 vaccine used.

Flu† Two doses given at least 4 weeks apart are recommended for children age 6 months through 8 years of age who are getting an influenza (flu) vaccine for the first time and for some other children in this age group.

HepA* Two doses of Hep A vaccine are needed for lasting protection. The 2 doses should be given between age 12 and 23 months. Both doses should be separated by at least 6 months. Children 2 years and older who have not received 2 doses of Hep A should complete the series.

ADDITIONAL INFORMATION

1. If your child misses a shot recommended for their age, talk to your child's doctor as soon as possible to see when the missed shot can be given.

2. If your child has any medical conditions that put them at risk for infection (e.g., sickle cell, HIV infection, cochlear implants) or is traveling outside the United States, talk to your child's doctor about additional vaccines that they may need.

Talk with your child's doctor if you have questions about any shot recommended for your child.



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

FOR MORE INFORMATION

Call toll-free: 1-800-CDC-INFO (1-800-232-4636)
Or visit: [cdc.gov/vaccines/parents](https://www.cdc.gov/vaccines/parents)



American Academy of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN™

Table 2 Recommended Adult Immunization Schedule by Medical Condition or Other Indication, United States, 2023

Vaccine	Pregnancy	Immuno-compromised (excluding HIV infection)	HIV infection CD4 percentage and count		Asplenia, complement deficiencies	End-stage renal disease, or on hemodialysis	Heart or lung disease; alcoholism ^a	Chronic liver disease	Diabetes	Health care personnel ^b	Men who have sex with men
			<15% or <200 mm ³	≥15% and ≥200 mm ³							
COVID-19		See Notes									
IIV4 or RIV4 or LAIV4	1 dose annually					Precaution			1 dose annually		
Tdap or Td	1 dose Tdap each pregnancy	1 dose Tdap, then Td or Tdap booster every 10 years									
MMR	Contraindicated ^c	Contraindicated	1 or 2 doses depending on indication								
VAR	Contraindicated ^c	Contraindicated		2 doses							
RZV		2 doses at age ≥19 years			2 doses at age ≥50 years						
HPV	Not Recommended ^c	3 doses through age 26 years			2 or 3 doses through age 26 years depending on age at initial vaccination or condition						
Pneumococcal (PCV15, PCV20, PPSV23)		1 dose PCV15 followed by PPSV23 OR 1 dose PCV20 (see notes)									
HepA				2, 3, or 4 doses depending on vaccine							
HepB	3 doses (see notes)	2, 3, or 4 doses depending on vaccine or condition									
MenACWY	1 or 2 doses depending on indication, see notes for booster recommendations										
MenB	Precaution	2 or 3 doses depending on vaccine and indication, see notes for booster recommendations									
Hib		3 doses HSCT ^c recipients only		1 dose							

 Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection
 Recommended vaccination for adults with an additional risk factor or another indication
 Recommended vaccination based on shared clinical decision-making
 Precaution—vaccination might be indicated if benefit of protection outweighs risk of adverse reaction
 Contraindicated or not recommended—vaccine should not be administered.
 No recommendation/Not applicable

^a. Precaution for LAIV4 does not apply to alcoholism. ^b. See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations. ^c. Hematopoietic stem cell transplant.

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger

UNITED STATES
2023

Vaccines in the Child and Adolescent Immunization Schedule*

Vaccine	Abbreviation(s)	Trade name(s)
COVID-19†	1vCOV-mRNA	Comirnaty®/Pfizer-BioNTech COVID-19 Vaccine
	2vCOV-mRNA	SPIKEVAX®/Moderna COVID-19 Vaccine Pfizer-BioNTech COVID-19 Vaccine, Bivalent
	1vCOV-aPS	Moderna COVID-19 Vaccine, Bivalent Novavax COVID-19 Vaccine
Dengue vaccine	DEN4CYD	Dengvaxia®
Diphtheria, tetanus, and acellular pertussis vaccine	DTaP	Daptacel® Infanrix®
Diphtheria, tetanus vaccine	DT	No trade name
Haemophilus influenzae type b vaccine	Hib (PRP-T)	ActHIB® Hiberix® PedvaxHIB®
Hepatitis A vaccine	Hib (PRP-OMP)	Havrix® Vaqta®
Hepatitis B vaccine	HepB	Engerix-B® Recombivax HB®
Human papillomavirus vaccine	HPV	Gardasil 9®
Influenza vaccine (inactivated)†	IIV4	Multiple
Influenza vaccine (live, attenuated)†	LAIV4	FluMist® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II® Priorix®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D	Menactra®
	MenACWY-CRM	Menveo®
	MenACWY-TT	MenQuadfi®
Meningococcal serogroup B vaccine	MenB-4C	Bexsero®
	MenB-FHbp	Trumenba®
Pneumococcal conjugate vaccine†	PCV13	Prenar 13®
	PCV15	Vaxneuvance™
Pneumococcal polysaccharide vaccine†	PPSV23	Pneumovax 23®
Poliovirus vaccine (inactivated)†	IPV	IPOL®
Rotavirus vaccine	RV1	Rotarix®
	RV5	RotaTeq®
Tetanus, diphtheria, and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Tetanus and diphtheria vaccine	Td	Tenivac® Tdvax™
Varicella vaccine	VAR	Varivax®
Combination vaccines (use combination vaccines instead of separate injections when appropriate)		
DTaP, hepatitis B, and inactivated poliovirus vaccine	DTaP-HepB-IPV	Pediarix®
DTaP, inactivated poliovirus, and Haemophilus influenzae type b vaccine	DTaP-IPV/Hib	Pentacel®
DTaP and inactivated poliovirus vaccine	DTaP-IPV	Kinrix® Quadracel®
DTaP, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B vaccine	DTaP-IPV-Hib-HepB	Vaxelis®
Measles, mumps, rubella, and varicella vaccine	MMRV	ProQuad®
New Vaccines and Other Immunizing Agents added to the Child/Adolescent Immunization Schedule in 2023 (See Addendum)		
RSV monoclonal antibody (Nirsevimab)	RSV-mAb	Bevyfortus™
Pneumococcal conjugate vaccine	PCV20	Prenar 20™

*Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

†COVID-19, Poliovirus, Influenza, and Pneumococcal vaccines have new or updated ACIP recommendations. Please see Addendum for more details.

How to use the child and adolescent immunization schedule

- 1** Determine recommended vaccine by age (Table 1)
- 2** Determine recommended interval for catch-up vaccination (Table 2)
- 3** Assess need for additional recommended vaccines by medical condition or other indication (Table 3)
- 4** Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
- 5** Review contraindications and precautions for vaccine types (Appendix)
- 6** Review new or updated ACIP guidance (Addendum)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American Academy of Pediatrics (www.aap.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Associates (www.aapa.org), and National Association of Pediatric Nurse Practitioners (www.napnap.org).

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or 800-822-7967

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays



Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- General Best Practice Guidelines for Immunization (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/vaccines/pubs/surv-manual
- ACIP Shared Clinical Decision-Making Recommendations www.cdc.gov/vaccines/acip/acip-scdm-faqs.html

Scan QR code for access to online schedule



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

Addendum

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2023

In addition to the recommendations presented in the previous sections of this Immunization Schedule, ACIP has approved the following recommendations by majority vote since October 20, 2022. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in *Morbidity and Mortality Weekly Report (MMWR)*.

Vaccines and Other Immunizing Agents	Recommendation	Effective Date of Recommendation*
COVID-19 (Moderna, Pfizer-BioNTech)	<ul style="list-style-type: none"> All persons ≥ 6 months of age should receive 2023–2024 (monovalent, XBB containing) COVID-19 vaccines as authorized under EUA or approved by BLA. For detailed information, see: www.cdc.gov/covidschedule 	September 12, 2023
Respiratory syncytial virus [RSV-mAb (Nirsevimab)]	<ul style="list-style-type: none"> All infants younger than 8 months and born shortly before or during the RSV season should receive 1 dose of nirsevimab within 1 week of birth either in hospital or outpatient setting Infants younger than age 8 months not born during RSV season and now entering their first RSV season should receive 1 dose of nirsevimab shortly before the start of RSV season Infants aged 8–19 months with chronic lung disease of prematurity requiring medical support (e.g., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before start of the second RSV season; severe immunocompromise; cystic fibrosis with weight for length <10th percentile; or with manifestation of severe lung disease (e.g., previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable) should receive 1 dose of nirsevimab shortly before start of second RSV season Infants 8–19 months who are American Indian or Alaska Native should receive 1 dose of nirsevimab before start of second RSV season Infants who are age-eligible and undergoing cardiac surgery with cardiopulmonary bypass should receive 1 additional dose of nirsevimab after surgery For detailed information, see: www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm?s_cid=mm7234a4_w 	August 3, 2023
Poliovirus (IPV)	<ul style="list-style-type: none"> Adolescents age 18 years who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary vaccination series with inactivated polio vaccine (IPV). Adolescents age 18 years who have received a primary series of trivalent oral polio vaccine (tOPV) or IPV in any combination and who are at increased risk of poliovirus exposure may receive another dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose with IPV for adults. 	June 27, 2023
Influenza (IIV4, ccIV4, RIV4, LAIV4)	<ul style="list-style-type: none"> All persons ages ≥ 6 months with egg allergy should receive influenza vaccine. Any influenza vaccine (egg based or non-egg based) that is otherwise appropriate for the recipient's age and health status can be used. Affirm the updated <i>MMWR</i> Recommendations and Reports, "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 Influenza Season" www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm 	June 27, 2023
Pneumococcal (PCV15, PCV20)	<ul style="list-style-type: none"> Use of either pneumococcal conjugate vaccines (PCV) PCV15 or PCV20 is recommended for all children aged 2–23 months according to currently recommended PCV dosing and schedules. For children with an incomplete PCV vaccination status, use of either PCV15 or PCV20 according to currently recommended PCV dosing and schedules is recommended for: <ul style="list-style-type: none"> Healthy children aged 24–59 months Children with specified health conditions(2) aged 24 through 71 months For children aged 2–18 years with any risk condition who have received all recommended doses of PCV before age 6 years <ul style="list-style-type: none"> Using ≥ 1 dose(s) of PCV20: No additional doses of any pneumococcal vaccine are indicated. This recommendation may be updated as additional data become available. Using PCV13 or PCV15 (no PCV20): A dose of PCV20 or PPSV23 using previously recommended dosing and schedules is recommended. For children aged 6–18 years with any risk condition who have not received any dose of PCV13, PCV15, or PCV20, a single dose of PCV15 or PCV20 is recommended. When PCV15 is used, it should be followed by a dose of PPSV23 at least 8 weeks later if not previously given. 	June 27, 2023

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official

Addendum

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2023

In addition to the recommendations presented in the previous sections of this Immunization Schedule, ACIP has approved the following recommendations by majority vote since October 20, 2022. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in *Morbidity and Mortality Weekly Report (MMWR)*.

Vaccines and Other Immunizing Agents	Recommendation	Effective Date of Recommendation*
COVID-19 (Moderna, Pfizer-BioNTech)	<ul style="list-style-type: none"> All persons ≥ 6 months of age should receive 2023–2024 (monovalent, XBB containing) COVID-19 vaccines as authorized under EUA or approved by BLA. For detailed information, see: www.cdc.gov/covidschedule 	September 12, 2023
Respiratory syncytial virus [RSV-mAb (Nirsevimab)]	<ul style="list-style-type: none"> All infants younger than 8 months and born shortly before or during the RSV season should receive 1 dose of nirsevimab within 1 week of birth either in hospital or outpatient setting Infants younger than age 8 months not born during RSV season and now entering their first RSV season should receive 1 dose of nirsevimab shortly before the start of RSV season Infants aged 8–19 months with chronic lung disease of prematurity requiring medical support (e.g., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before start of the second RSV season; severe immunocompromise; cystic fibrosis with weight for length <10th percentile; or with manifestation of severe lung disease (e.g., previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable) should receive 1 dose of nirsevimab shortly before start of second RSV season Infants 8–19 months who are American Indian or Alaska Native should receive 1 dose of nirsevimab before start of second RSV season Infants who are age-eligible and undergoing cardiac surgery with cardiopulmonary bypass should receive 1 additional dose of nirsevimab after surgery For detailed information, see: www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm?s_cid=mm7234a4_w 	August 3, 2023
Poliovirus (IPV)	<ul style="list-style-type: none"> Adolescents age 18 years who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary vaccination series with inactivated polio vaccine (IPV). Adolescents age 18 years who have received a primary series of trivalent oral polio vaccine (tOPV) or IPV in any combination and who are at increased risk of poliovirus exposure may receive another dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose with IPV for adults. 	June 27, 2023
Influenza (IIV4, ccIV4, RIV4, LAIV4)	<ul style="list-style-type: none"> All persons ages ≥ 6 months with egg allergy should receive influenza vaccine. Any influenza vaccine (egg based or non-egg based) that is otherwise appropriate for the recipient's age and health status can be used. Affirm the updated <i>MMWR</i> Recommendations and Reports, "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 Influenza Season" www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm 	June 27, 2023
Pneumococcal (PCV15, PCV20)	<ul style="list-style-type: none"> Use of either pneumococcal conjugate vaccines (PCV) PCV15 or PCV20 is recommended for all children aged 2–23 months according to currently recommended PCV dosing and schedules. For children with an incomplete PCV vaccination status, use of either PCV15 or PCV20 according to currently recommended PCV dosing and schedules is recommended for: <ul style="list-style-type: none"> Healthy children aged 24–59 months Children with specified health conditions(2) aged 24 through 71 months For children aged 2–18 years with any risk condition who have received all recommended doses of PCV before age 6 years <ul style="list-style-type: none"> Using ≥ 1 dose(s) of PCV20: No additional doses of any pneumococcal vaccine are indicated. This recommendation may be updated as additional data become available. Using PCV13 or PCV15 (no PCV20): A dose of PCV20 or PPSV23 using previously recommended dosing and schedules is recommended. For children aged 6–18 years with any risk condition who have not received any dose of PCV13, PCV15, or PCV20, a single dose of PCV15 or PCV20 is recommended. When PCV15 is used, it should be followed by a dose of PPSV23 at least 8 weeks later if not previously given. 	June 27, 2023

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official.

Addendum

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2023

In addition to the recommendations presented in the previous sections of this Immunization Schedule, ACIP has approved the following recommendations by majority vote since October 20, 2022. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in *Morbidity and Mortality Weekly Report (MMWR)*.

Vaccines and Other Immunizing Agents	Recommendation	Effective Date of Recommendation*
COVID-19 (Moderna, Pfizer-BioNTech)	<ul style="list-style-type: none"> All persons ≥ 6 months of age should receive 2023–2024 (monovalent, XBB containing) COVID-19 vaccines as authorized under EUA or approved by BLA. For detailed information, see: www.cdc.gov/covidschedule 	September 12, 2023
Respiratory syncytial virus [RSV-mAb (Nirsevimab)]	<ul style="list-style-type: none"> All infants younger than 8 months and born shortly before or during the RSV season should receive 1 dose of nirsevimab within 1 week of birth either in hospital or outpatient setting Infants younger than age 8 months not born during RSV season and now entering their first RSV season should receive 1 dose of nirsevimab shortly before the start of RSV season Infants aged 8–19 months with chronic lung disease of prematurity requiring medical support (e.g., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before start of the second RSV season; severe immunocompromise; cystic fibrosis with weight for length <10th percentile; or with manifestation of severe lung disease (e.g., previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable) should receive 1 dose of nirsevimab shortly before start of second RSV season Infants 8–19 months who are American Indian or Alaska Native should receive 1 dose of nirsevimab before start of second RSV season Infants who are age-eligible and undergoing cardiac surgery with cardiopulmonary bypass should receive 1 additional dose of nirsevimab after surgery For detailed information, see: www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm?s_cid=mm7234a4_w 	August 3, 2023
Poliovirus (IPV)	<ul style="list-style-type: none"> Adolescents age 18 years who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary vaccination series with inactivated polio vaccine (IPV). Adolescents age 18 years who have received a primary series of trivalent oral polio vaccine (tOPV) or IPV in any combination and who are at increased risk of poliovirus exposure may receive another dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose with IPV for adults 	June 27, 2023
Influenza (IIV4, ccIV4, RIV4, LAIV4)	<ul style="list-style-type: none"> All persons ages ≥ 6 months with egg allergy should receive influenza vaccine. Any influenza vaccine (egg based or non-egg based) that is otherwise appropriate for the recipient's age and health status can be used. Affirm the updated <i>MMWR</i> Recommendations and Reports, "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 Influenza Season" www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm 	June 27, 2023
Pneumococcal (PCV15, PCV20)	<ul style="list-style-type: none"> Use of either pneumococcal conjugate vaccines (PCV) PCV15 or PCV20 is recommended for all children aged 2–23 months according to currently recommended PCV dosing and schedules. For children with an incomplete PCV vaccination status, use of either PCV15 or PCV20 according to currently recommended PCV dosing and schedules is recommended for: <ul style="list-style-type: none"> Healthy children aged 24–59 months Children with specified health conditions(2) aged 24 through 71 months For children aged 2–18 years with any risk condition who have received all recommended doses of PCV before age 6 years <ul style="list-style-type: none"> Using ≥ 1 dose(s) of PCV20: No additional doses of any pneumococcal vaccine are indicated. This recommendation may be updated as additional data become available. Using PCV13 or PCV15 (no PCV20): A dose of PCV20 or PPSV23 using previously recommended dosing and schedules is recommended. For children aged 6–18 years with any risk condition who have not received any dose of PCV13, PCV15, or PCV20, a single dose of PCV15 or PCV20 is recommended. When PCV15 is used, it should be followed by a dose of PPSV23 at least 8 weeks later if not previously given. 	June 27, 2023

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official